Stress-related neuropeptides and alcoholism: CRH, NPY, and beyond |
| |
Authors: | Roberto Ciccocioppo Donald R Gehlert Simranjit Kaur Annika Thorsell Philip A Hipskind Jianliang Lu Jeffrey Cramer David McKinzie Daina Economidou Nazzareno Cannella Marsida Kallupi Maurizio Massi Jody Gilman Johannes T Tauscher Daniel Hommer |
| |
Institution: | a Department of Experimental Medicine and Public Health, University of Camerino, Via madonna delle Carceri, 62032 Camerino, Macerata, Italy b Lilly Research Laboratories, Indianapolis, IN 46285, USA c Department of Behavioral Neuroscience, Oregon Health and Sciences University, Portland, OR 97239, USA d Laboratory of Clinical and Translational Studies, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892, USA e Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario M5S 2S1, Canada f Department of Anatomy and Developmental Biology, University College London, London WC1E 6BT, UK |
| |
Abstract: | This article summarizes the proceedings of a symposium held at the conference on “Alcoholism and Stress: A Framework for Future Treatment Strategies” in Volterra, Italy, May 6-9, 2008. Chaired by Markus Heilig and Roberto Ciccocioppo, this symposium offered a forum for the presentation of recent data linking neuropetidergic neurotransmission to the regulation of different alcohol-related behaviors in animals and in humans. Dr. Donald Gehlert described the development of a new corticotrophin-releasing factor receptor 1 antagonist and showed its efficacy in reducing alcohol consumption and stress-induced relapse in different animal models of alcohol abuse. Dr. Andrey Ryabinin reviewed recent findings in his laboratory, indicating a role of the urocortin 1 receptor system in the regulation of alcohol intake. Dr. Annika Thorsell showed data supporting the significance of the neuropeptide Y receptor system in the modulation of behaviors associated with a history of ethanol intoxication. Dr. Roberto Ciccocioppo focused his presentation on the nociceptin/orphanin FQ (N/OFQ) receptors as treatment targets for alcoholism. Finally, Dr. Markus Heilig showed recent preclinical and clinical evidence suggesting that neurokinin 1 antagonism may represent a promising new treatment for alcoholism. Collectively, these investigators highlighted the significance of neuropeptidergic neurotransmission in the regulation of neurobiological mechanisms of alcohol addiction. Data also revealed the importance of these systems as treatment targets for the development of new medication for alcoholism. |
| |
Keywords: | CRH Nociceptin/orphanin FQ Neurokinins Substance P Neuropeptide Y Urocortin |
本文献已被 ScienceDirect 等数据库收录! |
|